Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Therapeutic Advances in Medical Oncology|October 25, 2021
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, et al.
Journal of Clinical Medicine|June 5, 2020
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III TrialGabriel Rinnerthaler, Simon Peter Gampenrieder, Hubert Hackl, et al.
Cancers|May 16, 2023
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study GroupBettina Jansko-Gadermeir, Michael Leisch, Franz J Gassner, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2021
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trialFelix Keil, Maximilian Hartl, Gabriela Altorjai, et al.
European Journal of Haematology|February 7, 2019
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIMFlorian Huemer, Thomas Melchardt, Bettina Jansko, et al.
Wiener Klinische Wochenschrift|December 14, 2018
Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
British Journal of Cancer|October 21, 2016
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patientsKatharina T Prochazka, Thomas Melchardt, Florian Posch, et al.
Wiener Klinische Wochenschrift|September 16, 2021
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMTTeresa Magnes, Sandro M Wagner, Thomas Melchardt, et al.
Wiener Klinische Wochenschrift|July 26, 2018
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy managementMaria-Theresa Krauth, Sonja Burgstaller, Veronika Buxhofer-Ausch, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinomaAngelika Martina Starzer, Gerwin Heller, Erwin Tomasich, et al.
Pageof 9